AHL Partners LLP Invests $842,000 in China Biologic Products, Inc. (CBPO)

AHL Partners LLP purchased a new position in China Biologic Products, Inc. (NASDAQ:CBPO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,445 shares of the biopharmaceutical company’s stock, valued at approximately $842,000.

Several other large investors have also bought and sold shares of CBPO. Oppenheimer Asset Management Inc. purchased a new position in shares of China Biologic Products in the first quarter worth about $156,000. Nomura Holdings Inc. purchased a new position in shares of China Biologic Products in the first quarter worth about $463,000. Jennison Associates LLC lifted its stake in shares of China Biologic Products by 0.8% in the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 44 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 3,053 shares in the last quarter. Finally, Citigroup Inc. lifted its stake in shares of China Biologic Products by 59.4% in the second quarter. Citigroup Inc. now owns 11,748 shares of the biopharmaceutical company’s stock worth $1,329,000 after buying an additional 4,378 shares in the last quarter. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “AHL Partners LLP Invests $842,000 in China Biologic Products, Inc. (CBPO)” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/10/18/ahl-partners-llp-invests-842000-in-china-biologic-products-inc-cbpo.html.

Several equities analysts have recently weighed in on CBPO shares. BidaskClub downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a research note on Friday, August 4th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. China Biologic Products presently has an average rating of “Hold” and an average price target of $137.50.

Shares of China Biologic Products, Inc. (CBPO) opened at 81.27 on Wednesday. The firm has a market capitalization of $2.21 billion, a PE ratio of 21.15 and a beta of 1.75. The firm’s 50 day moving average is $93.15 and its 200-day moving average is $103.13. China Biologic Products, Inc. has a 12 month low of $79.92 and a 12 month high of $125.99.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly ea

Several other large investors have also bought and sold shares of CBPO. Oppenheimer Asset Management Inc. purchased a new position in shares of China Biologic Products in the first quarter worth about $156,000. Nomura Holdings Inc. purchased a new position in shares of China Biologic Products in the first quarter worth about $463,000. Jennison Associates LLC lifted its stake in shares of China Biologic Products by 0.8% in the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 44 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 3,053 shares in the last quarter. Finally, Citigroup Inc. lifted its stake in shares of China Biologic Products by 59.4% in the second quarter. Citigroup Inc. now owns 11,748 shares of the biopharmaceutical company’s stock worth $1,329,000 after buying an additional 4,378 shares in the last quarter. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “AHL Partners LLP Invests $842,000 in China Biologic Products, Inc. (CBPO)” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/10/18/ahl-partners-llp-invests-842000-in-china-biologic-products-inc-cbpo.html.

Several equities analysts have recently weighed in on CBPO shares. BidaskClub downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a research note on Friday, August 4th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. China Biologic Products presently has an average rating of “Hold” and an average price target of $137.50.

Shares of China Biologic Products, Inc. (CBPO) opened at 81.27 on Wednesday. The firm has a market capitalization of $2.21 billion, a PE ratio of 21.15 and a beta of 1.75. The firm’s 50 day moving average is $93.15 and its 200-day moving average is $103.13. China Biologic Products, Inc. has a 12 month low of $79.92 and a 12 month high of $125.99.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.05. The business had revenue of $89.28 million for the quarter, compared to analyst estimates of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The company’s revenue was down 2.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.26 EPS. On average, analysts expect that China Biologic Products, Inc. will post $4.95 EPS for the current fiscal year.

China Biologic Products Company Profile

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply